Global Brain Cancer Therapeutics Market Set to Surpass USD 5.1 Billion by 2030,

NEW YORK - May 16, 2025 - PRLog -- The global brain cancer therapeutics market is poised for significant growth, with projections indicating an increase from USD 3.3 billion in 2024 to USD 5.1 billion by 2030. This growth, at a CAGR of 7.3% during the forecast period,

Brain Cancer Therapeutics Market Overview: Key Drivers and Developments

• Robust Pipeline of Therapies: Pharmaceutical companies and research institutions are actively developing new drugs and therapies, addressing the unmet medical needs in brain cancer treatment.
• Government Initiatives: Governments worldwide are expanding healthcare infrastructure and subsidizing treatment costs. For instance, the U.S. has implemented programs like Medicare and Medicaid to ensure accessible treatment.
• FDA Approvals: In August 2024, the FDA approved Voranigo (vorasidenib) for Grade 2 IDH-mutant glioma, marking a significant advancement in targeted brain cancer therapy.

Ready to explore? 🌍 Download the Sample PDF now! 📥 - https://www.marknteladvisors.com/query/request-sample/brain-cancer-therapeutics-market.html

Key Takeaways from the Market Research Report

• Rising Demand for Personalized Therapies: Approximately 65% of brain tumor patients are now being treated with targeted therapies, reflecting a shift towards precision medicine.
• Increased Investment in Research: Emerging players are infusing fresh momentum into research and development, contributing to the commercialization of innovative treatments.

Leading Innovators in the Market

Prominent players driving innovation and growth in the brain cancer therapeutics market include:

• Amgen Inc.
• AstraZeneca PLC
• Product Portfolio
• Bayer AG
• Kazia Therapeutics Ltd.

Brain Cancer Therapeutics Market Segmentation Analysis 2030

By Type

• Glioblastoma
• Meningioma
• Pituitary Tumors
• Others

By Therapy

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Other

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Spotlight on Targeted Therapy: A Game-Changer in Brain Cancer Treatment

The approval of Voranigo (vorasidenib) by the FDA in August 2024 represents a significant milestone in targeted brain cancer therapy. As the first systemic therapy approved for Grade 2 IDH-mutant glioma, Voranigo offers a new treatment avenue for patients with this specific genetic mutation.

Leading Segment: Glioblastoma

Glioblastoma, known for its aggressive nature and poor prognosis, remains the most prevalent and challenging brain tumor to treat.

Regional Insights: North America at the Forefront

North America holds the leading position in the brain cancer therapeutics market, attributed to its advanced healthcare infrastructure, significant investment in research and development, and supportive regulatory environment.

Future Outlook

With the growing trends, the brain cancer therapeutics industry is projected to expand during the forecast years (2025-2030), as the aforementioned factors are transforming the market landscape and creating new opportunities for stakeholders.

Read Full Report - https://www.marknteladvisors.com/research-library/brain-cancer-therapeutics-market.html